The Institute of Clinical Pharmacology, led by Prof. Kobold, is participating in the German Pancreatic Cancer Alliance, funded by the Deutsche Krebshilfe with €33.5 million. The institute contributes to the consortium DEFEAT-PDAC (Deciphering and Therapeutic Targeting of the PDAC Ecosystem), which aims to overcome key challenges in pancreatic cancer treatment: patient-to-patient molecular differences and dense tumor environments that block therapies. The consortium focuses on identifying tumor vulnerabilities and developing immunotherapies that target both cancer cells and their microenvironment. Led by Dieter Saur at the TUM Klinikum Rechts der Isar, DEFEAT-PDAC brings together researchers from leading German and international institutions, aiming to create innovative, patient-centered therapies.